Thomas Jefferson University
News & Events

<< Back to News & Events List

Study Nearly Triples the Locations in the Human Genome that Harbor MicroRNAs


(PHILADELPHIA) – According to the public databases, there are currently approximately 1,900 locations  in the human genome that produce microRNAs (miRNAs), the small and powerful non-coding molecules that regulate numerous cellular processes by reducing the abundance of their targets.  New research published in the Proceedings of the National Academy of Sciences (PNAS) this week adds another roughly 3,400 such locations to that list. Many of the miRNA molecules that are produced from these newly discovered locations are tissue-specific and also human-specific. The finding has big implications for research into how miRNAs drive disease.

“By analyzing human deep-sequencing data, we discovered many new locations in the human genome that produce miRNAs. Our findings effectively triple the number of miRNA-generating loci that are now known” says Isidore Rigoutsos, Ph.D., Director of the Computational Medicine Center at Thomas Jefferson University, who led the study.  “This new collection will help researchers gain insights into the multiple roles that miRNAs play in various tissues and diseases.”

For nearly three years, the team collected and sequenced RNA from dozens of healthy and diseased individuals. The samples came from pancreas, breast, platelets, blood, prostate, and brain.  To their collection they also added publicly available data eventually reaching more than 1,300 analyzed samples representing 13 human tissue types. Their analyses uncovered 3,356 new locations in the human genome that generate over 3,700 previously undescribed miRNAs.

For a handful of the 13 tissues they studied, the team also had access to information describing miRNA association with Argonaute, an essential protein member of the regulatory complex that enables miRNA to interact with their targets. They found that 45 percent of the newly discovered miRNAs were in fact associated with Argonaute, a further indication that these molecules are involved in gene regulation. “We anticipate that many more of the newly discovered miRNAs will be found loaded on Argonaute as additional such data become available for the other tissues,” says Eric Londin, Ph.D., an Assistant Professor and co-first author together with Phillipe Loher, M.S., a computational biologist and software engineer, both members of Jefferson’s Computational Medicine Center.

One of the key design choices that the team made was to not limit their search to conserved genomic sequences, i.e. to only those sequences that are shared across multiple organisms. Instead the researchers scanned the genome much more broadly. “Advances in sequencing technology of the last several years made it easier to generate more data, from more tissues, and do so faster,” says Dr. Rigoutsos who is also a researcher at the Sidney Kimmel Cancer Center at Thomas Jefferson University. “Investigating the alluring possibility that miRNAs with important roles might exist only in humans was within reach. And this is what we set out to do.”

Of the new molecules, 56.7 are specific to humans and most of them (94.4 percent) are found only in primates. Because of this organism-specificity these RNA molecules are involved in regulatory events that are absent from model organisms such as mouse and the fruit fly.

Tissue-specificity is another important characteristic of these new miRNAs. It means that these molecules are behind molecular events that are present in a single tissue, or in only a few tissues. Some of these molecules could potentially prove useful as novel tissue-specific disease biomarkers.

The tissue- and primate-specificity of the new molecules are expected to have important implications for the community’s attempts to understand the causes of diseases. A first step in that direction requires the identification and validation of the targets for each of these 3,707 new miRNAs. To assist in these efforts, the team generated computational predictions of each miRNA’s putative targets that are available from the Computational Medicine Center’s website.  

This research was supported by a grant from the W. M. Keck Foundation, the Hirshberg Foundation for Pancreatic Cancer Research, the Tolz Foundation Weizmann Institute of Science-Thomas Jefferson University Collaboration Program, a Pilot Project Award by the NIH Autoimmune Centers of Excellence (2U19-AI056363-06/2030984) the NIH-NCI Cancer Center Core grant (P30CA56036), by TJU Institutional funds. Study authors were also supported by the following grants: NIH grant CA140424, Lifespan/Tufts/Brown Center for AIDS Research (P30 AI042853), NIH Grants AG042419, NS085830 and AG028383, NIH/NIAMS grant R01 AR 19616, CLL Global Research Foundation, by a sister Institution Network Foundation MDACC-DKFZ grant on CLL, the Laura and John Arnold Foundation, the RGK Foundation and the Estate of C.G. Johnson Jr, the Jefferson Pancreas, Biliary and Related Cancer Center, grant HL102482 from the Heart, Lung and Blood Institute of the National Institute of Health, the PA CURE grant, NIH grant CA099996, NIH grant GM106047, and DOD grant PC094507.

Paper reference: E.R. Londin, P. Loher, et al., “Analysis of 13 cell types reveals evidence for the

expression of numerous novel primate- and tissue-specific microRNAs,” PNAS, DOI 10.1073/pnas.1420955112, 2015.

For more information, contact Edyta Zielinska, 215-955-5291,

Jefferson’s Computational Medicine Center was founded in 2010. The Center focuses on organism-specific non-coding regulatory RNAs. The Center’s researchers combine computational and experimental techniques to understand how such non-coding RNAs drive the onset and progression of diseases.

About Jefferson — Health is all we do.

Thomas Jefferson University, Thomas Jefferson University Hospitals and Jefferson University Physicians are partners in providing the highest-quality, compassionate clinical care for patients, educating the health professionals of tomorrow, and discovering new treatments and therapies that will define the future of healthcare. Thomas Jefferson University enrolls more than 3,600 future physicians, scientists and healthcare professionals in the Sidney Kimmel Medical College (SKMC); Jefferson Schools of Health Professions, Nursing, Pharmacy, Population Health; and the Graduate School of Biomedical Sciences, and is home of the National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center. Jefferson University Physicians is a multi-specialty physician practice consisting of over 650 SKMC full-time faculty. Thomas Jefferson University Hospitals is the largest freestanding academic medical center in Philadelphia. Services are provided at five locations — Thomas Jefferson University Hospital  and Jefferson Hospital for Neuroscience in Center City Philadelphia; Methodist Hospital in South Philadelphia; Jefferson at the Navy Yard; and Jefferson at Voorhees in South Jersey.